Payment overview · 2025
General Payments
$4,683.97
236 reported records · 32 companies
Healthcare provider profile · identity verified
Theodros Mengesha, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · MADISON, AL · NPI 1184771909
Verified facts
What the public records show
CMS Open Payments records show Theodros Mengesha, MD received $4,683.97 in general payments during 2025 across 236 reported records.
PFIZER INC. accounted for 10.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Qulipta, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Qulipta by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fycompa by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $494.92 | 10.6% | 27 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $430.15 | 9.2% | 29 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $333.78 | 7.1% | 17 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $303.17 | 6.5% | 14 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $271.40 | 5.8% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $263.83 | 5.6% | 14 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $257.41 | 5.5% | 14 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $250.49 | 5.3% | 15 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$213.75 | 4.6% | 12 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $181.53 | 3.9% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $177.76 | 3.8% | 9 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $176.82 | 3.8% | 6 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $159.35 | 3.4% | 8 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $156.87 | 3.4% | 9 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$148.99 | 3.2% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $139.64 | 3.0% | 7 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $110.57 | 2.4% | 6 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $94.10 | 2.0% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $85.38 | 1.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.24 | 1.6% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $62.23 | 1.3% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$41.82 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.46 | 0.8% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $37.51 | 0.8% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $35.79 | 0.8% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $28.63 | 0.6% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.51 | 0.5% | 1 | 2025 |
| Amicus Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.25 | 0.5% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $20.69 | 0.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.45 | 0.4% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $15.81 | 0.3% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.67 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,683.97 | 236 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $472.03 | 26 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $472.03 | 26 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $333.78 | 17 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $312.17 | 17 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $303.17 | 14 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $271.40 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $254.29 | 13 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $250.49 | 15 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $250.49 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $226.78 | 12 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $213.75 | 12 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $205.22 | 17 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $181.53 | 6 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $159.35 | 8 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $139.64 | 7 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $123.00 | 6 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $122.59 | 7 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $102.34 | 5 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $85.38 | 4 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $83.00 | 5 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $83.00 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $82.30 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $74.57 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $56.84 | 3 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $55.69 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $45.71 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $41.82 | 1 | 2025 |
Source payment records
|
|||||
| PLEGRIDY Normalized: plegridy |
Biological | Biogen, Inc. | $40.20 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $37.51 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $35.79 | 2 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | MDD US Operations, LLC | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 55 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 699 | 197 |
| Levetiracetam | Levetiracetam | 580 | 125 |
| Gabapentin | Gabapentin | 571 | 80 |
| Amitriptyline Hcl | Amitriptyline Hcl | 366 | 89 |
| Donepezil Hcl | Donepezil Hcl | 351 | 108 |
| Duloxetine Hcl | Duloxetine Hcl | 321 | 80 |
| Primidone | Primidone | 307 | 70 |
| Topiramate | Topiramate | 289 | 62 |
| Quetiapine Fumarate | Quetiapine Fumarate | 260 | 65 |
| Tizanidine Hcl | Tizanidine Hcl | 233 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 219 | 69 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 218 | 53 |
| Lamotrigine | Lamotrigine | 218 | 38 |
| Propranolol Hcl | Propranolol Hcl | 202 | 52 |
| Phenobarbital | Phenobarbital | 142 | 12 |
| Aimovig Autoinjector | Erenumab-Aooe | 141 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 33 |
| Lacosamide | Lacosamide | 105 | 15 |
| Oxcarbazepine | Oxcarbazepine | 102 | 18 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 102 | 18 |
| Atorvastatin Calcium | Atorvastatin Calcium | 101 | 35 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 96 | 26 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 95 | 27 |
| Trazodone Hcl | Trazodone Hcl | 93 | 32 |
| Zonisamide | Zonisamide | 92 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 90 | 14 |
| Pregabalin | Pregabalin | 84 | suppressed |
| Brilinta | Ticagrelor | 75 | 12 |
| Baclofen | Baclofen | 71 | 18 |
| Carbamazepine Er | Carbamazepine | 69 | 13 |
| Clonazepam | Clonazepam | 64 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 61 | 18 |
| Eliquis | Apixaban | 59 | 13 |
| Divalproex Sodium | Divalproex Sodium | 58 | 13 |
| Qulipta | Atogepant | 55 | 11 |
| Meclizine Hcl | Meclizine Hcl | 53 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 15 |
| Neupro | Rotigotine | 50 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 44 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 41 | 19 |
| Dilantin | Phenytoin Sodium Extended | 39 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 23 |
| Rivastigmine | Rivastigmine | 36 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | 11 |
| Meloxicam | Meloxicam | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 31 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Clobazam | Clobazam | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | 11 |
| Emgality Pen | Galcanezumab-Gnlm | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Teriflunomide | Teriflunomide | 19 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Dalfampridine Er | Dalfampridine | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Topiramate Er | Topiramate | 18 | suppressed |
| Azathioprine | Azathioprine | 16 | suppressed |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 16 | suppressed |
| Banzel | Rufinamide | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Keppra | Levetiracetam | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nourianz | Istradefylline | 13 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Dilantin | Phenytoin | 12 | suppressed |
| Fycompa | Perampanel | 12 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 12 | suppressed |
| Rufinamide | Rufinamide | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Lamictal Xr | Lamotrigine | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Lisinopril | Lisinopril | 11 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 11 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Tegretol Xr | Carbamazepine | 11 | suppressed |
| Xcopri | Cenobamate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,683.97 · 236 records | PFIZER INC. | AMPYRA, BOTOX, BRIUMVI, Briviact, EMGALITY, EPIDIOLEX, FIRDAPSE, Fintepla, Gamunex-C, Gocovri, INBRIJA, INCEPTIV, INGREZZA, KESIMPTA, KISUNLA, Leqembi, Motpoly XR, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, Ocrevus Zunovo, PANZYGA, PLEGRIDY, QULIPTA, QUTENZA, Qelbree, REXULTI, Rystiggo, SPRAVATO, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, Xeomin, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Qulipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error